Home › Hemophilia B
Hemophilia B clinical trials recruiting in the U.S.
12 studies for Hemophilia B are recruiting participants at sites across the United States.
Cities with the most studies
- Philadelphia, PA5 studies
- Los Angeles, CA4 studies
- Atlanta, GA4 studies
- Sacramento, CA4 studies
- Houston, TX4 studies
- Ann Arbor, MI4 studies
- Greenville, NC3 studies
- Seattle, WA3 studies
- Gainesville, FL3 studies
- Nashville, TN3 studies
- San Francisco, CA3 studies
By state
- California7 studies
- Florida4 studies
- Georgia4 studies
- Louisiana3 studies
- Michigan6 studies
- Missouri3 studies
- New York5 studies
- North Carolina4 studies
- Ohio3 studies
- Pennsylvania6 studies
- Tennessee4 studies
- Texas4 studies
- Washington3 studies
Recently updated studies
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RecruitingPhase 3
Ages 1 to 17 · Men · Updated Sep 23, 2026 · NCT05611801Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RecruitingPhase 3
138 Months – 206 Months · Men · Updated Sep 16, 2026 · NCT07080905A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RecruitingPhase 1/2
Ages 2 and older · Men · Updated Sep 11, 2026 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06003387SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
RecruitingPhase 3
Ages 6 and older · All sexes · Updated Aug 21, 2026 · NCT04563520ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
All ages · All sexes · Updated Aug 17, 2026 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 60 · All sexes · Updated Jul 2, 2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RecruitingPhase 3
Ages 1 to 74 · Men · Updated Jul 1, 2026 · NCT05145127Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
RecruitingPhase 3
Ages 18 and older · Men · Updated May 27, 2026 · NCT05568719ATHNdataset Registry
RecruitingObservational study
All ages · All sexes · Updated Apr 21, 2026 · NCT06820515An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 19, 2026 · NCT06008938SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
RecruitingPhase 4
Ages 12 to 100 · All sexes · Updated Jan 12, 2026 · NCT04647227From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.